Recursion Pharmaceuticals, Inc. (RXRX)
| Market Cap | 2.34B +2.3% |
| Revenue (ttm) | 54.86M -15.1% |
| Net Income | -518.88M |
| EPS | -1.02 |
| Shares Out | 536.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,501,287 |
| Open | 4.015 |
| Previous Close | 3.950 |
| Day's Range | 3.890 - 4.430 |
| 52-Week Range | 2.770 - 7.180 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 7.22 (+65.6%) |
| Est. Earnings | Nov 4, 2026 |
About RXRX
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat ... [Read more]
Financial Performance
In 2025, Recursion Pharmaceuticals's revenue was $74.68 million, an increase of 26.92% compared to the previous year's $58.84 million. Losses were -$644.76 million, 39.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price target is $7.22, which is an increase of 65.60% from the latest price.
News
Cathie Wood’s ARK Investment buys 1.9M shares of Recursion Pharmaceuticals today
20:03 EDT Cathie Wood’s ARK Investment buys 1.9M shares of Recursion Pharmaceuticals (RXRX) today
Cathie Wood’s ARK Investment buys 1.5M shares of Recursion Pharmaceuticals today
20:24 EDT Cathie Wood’s ARK Investment buys 1.5M shares of Recursion Pharmaceuticals (RXRX) today
Tempus AI, Recursion extend data license agreement, enter new license agreement
Tempus AI (TEM) announced an extension of its data license agreement with Recursion Pharmaceuticals (RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will li...
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies ...
Recursion Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has transformed into an end-to-end AI-driven drug discovery leader, achieving significant cost reductions and clinical progress with first-in-class assets like REC-4881 and REC-1245. Strategic partnerships with Genentech and Sanofi have generated over $525 million in milestones, while a proprietary data factory and integrated AI platform drive repeatable innovation.
Recursion Pharmaceuticals price target lowered to $5.30 from $5.50 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $5.30 from $5.50 and keeps an Equal Weight rating on the shares.
Recursion Pharmaceuticals Transcript: Bank of America SMID Cap Virtual Conference
Upstart Holdings presented at a major mid-cap conference, outlining its AI-driven lending platform, recent record profitability, and strategic focus on capital efficiency and product expansion. Leadership highlighted strong Q2 results, ongoing innovation, and a commitment to sustainable, profitable growth despite investor caution.
Recursion Pharmaceuticals Earnings Call Transcript: Q2 2026
Reached a pivotal stage with five clinical programs and over $500M in partnership inflows. Lowered 2026 OpEx guidance by 40% and ended the quarter with $557M in cash, ensuring runway through early 2028. Key milestones include REC-4881 phase II data and a first-in-class neuroscience target with Roche Genentech.
Recursion Pharmaceuticals Quarterly report: Q2 2026
Recursion Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 5, 2026.
Recursion Pharmaceuticals Earnings release: Q2 2026
Recursion Pharmaceuticals released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Recursion Pharmaceuticals Slides: Q2 2026
Recursion Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Recursion Pharmaceuticals reports Q2 EPS (25c), consensus (23c)
Reports Q2 revenue $7.7M, consensus $11.96M. Cash, cash equivalents and restricted cash were $556.8M as of June 30, compared to $753.9M as of December 31, 2025. Based on current operating…
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated tar...
Recursion to Participate in Upcoming Investor Conferences
Salt Lake City, UT, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation ...
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Salt Lake City, UT, July 31, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on July 27, 2026, t...
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) -- Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) – Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radica...
Cathie Wood’s ARK Investment buys 260K shares of Recursion Pharmaceuticals today
20:24 EDT Cathie Wood’s ARK Investment buys 260K shares of Recursion Pharmaceuticals (RXRX) today
Recursion Pharmaceuticals Transcript: AGM 2026
The meeting covered board elections, executive compensation, and auditor ratification, with all proposals approved. No questions were submitted by stockholders, and final voting results will be filed in a Form 8-K.
Recursion Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The platform integrates AI across biology, chemistry, and ClinTech to accelerate drug discovery and development, supported by major pharma partnerships and a diversified pipeline. Key clinical data readouts are expected over the next 12-18 months, with a strong focus on operational efficiency and risk diversification.
Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City
Altitude Lab portfolio companies surpass $205M in funding as startups advance clinical trials, sign global pharma deals, and reshape early-stage biotech.
Recursion Pharmaceuticals price target raised to $5.50 from $5 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Recursion Pharmaceuticals (RXRX) to $5.50 from $5 and keeps an Equal Weight rating on the shares.
Recursion Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
The company is advancing five clinical programs with near-term data, leveraging a unified AI-driven platform and proprietary data to improve drug discovery and trial efficiency. Strategic partnerships have generated over $500 million, while disciplined expense management supports a focus on high-impact programs.
Recursion Pharmaceuticals reports Q1 EPS (22c), consensus (26c)
Reports Q1 revenue $6.47B, consensus $15.78M. Cash, cash equivalents and restricted cash were $665.2M vs. $753.9M as of December 31, 2025. Continues to expect its cash runway to extend into…
Recursion Pharmaceuticals Earnings Call Transcript: Q1 2026
AI-driven platform advances have led to clinical proof in multiple programs, strong partner inflows, and a 30% reduction in operating expenses. Cash runway extends into early 2028, with multiple clinical milestones and regulatory engagements expected in the next 12-18 months.